Alterity Therapeutics
- Short interest
- 0.02%
- −0.09 pp 30d
- as of 8 Oct 2026
- Reported shorts
- 45K
- Shares on issue
- 229.151M
Alterity Therapeutics (ATH) Short Interest
Alterity Therapeutics (ASX:ATH) had 0.02% of shares reported as short positions as of 8 Oct 2026, representing 45,003 shares. Alterity Therapeutics operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Alterity Therapeutics
Alterity Therapeutics Limited focuses on developing therapies to treat neurodegenerative diseases associated with aging, like Alzheimer's and Parkinson's disease. The company leverages a novel drug development platform aimed at targeting misfolded proteins. Positioned as a pioneer in this field, Alterity aims to address significant unmet needs in the neurosciences market.
Company profile →Alterity Therapeutics (ASX:ATH) has 0.02% of its shares on issue reported as short positions as of 8 Oct 2026, or about 45,003 shares. Over the past 30 days that figure has fallen 0.09 percentage points, and over 90 days it has been broadly flat. Its highest recorded short interest was 1.18% in January 2024. ATH is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads ATH today
- Zanger BreakoutNot a candidate
- CAN SLIMNot a candidate
- Minervini Trend TemplateNot a candidate
- Crowded-Short BreakoutNot a candidate
- Quality compoundersWatchScore 15rank 944 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
ATH fundamentals
In the year to 30 Jun 2026, Alterity Therapeutics (ASX:ATH) recorded revenue of A$0 and a net loss after tax of A$23.4M. A year earlier it recorded revenue of A$0 and a net loss after tax of A$12.1M. Return on equity −55.0% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest ATH news
All news- We Think Alterity Therapeutics (ASX:ATH) Needs To Drive Business Growth Carefully - Simply Wall Street
googlenews · 8 Oct 2026
- Alterity to Present at Canaccord Drug and Device Conference
asx · 8 Oct 2026
- Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline
stockhead · 5 Oct 2026
Company details
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss ATH
Start a research thread or post the first pulse update